| Classifying cancers based on T-cell infiltration and PD-L1 MWL Teng, SF Ngiow, A Ribas, MJ Smyth Cancer research 75 (11), 2139-2145, 2015 | 1461 | 2015 |
| Cancer immunoediting and resistance to T cell-based immunotherapy JS O’Donnell, MWL Teng, MJ Smyth Nature reviews Clinical oncology 16 (3), 151-167, 2019 | 1435 | 2019 |
| Translational biology of osteosarcoma M Kansara, MW Teng, MJ Smyth, DM Thomas Nature Reviews Cancer 14 (11), 722-735, 2014 | 1114 | 2014 |
| Combination cancer immunotherapies tailored to the tumour microenvironment MJ Smyth, SF Ngiow, A Ribas, MWL Teng Nature reviews Clinical oncology 13 (3), 143-158, 2016 | 919 | 2016 |
| IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases MWL Teng, EP Bowman, JJ McElwee, MJ Smyth, JL Casanova, ... Nature medicine 21 (7), 719-729, 2015 | 879 | 2015 |
| De-novo and acquired resistance to immune checkpoint targeting NL Syn, MWL Teng, TSK Mok, RA Soo The Lancet Oncology 18 (12), e731-e741, 2017 | 755 | 2017 |
| Targeting immunosuppressive adenosine in cancer D Vijayan, A Young, MWL Teng, MJ Smyth Nature Reviews Cancer 17 (12), 709-724, 2017 | 734 | 2017 |
| Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease J Liu, SJ Blake, MCR Yong, H Harjunpää, SF Ngiow, K Takeda, A Young, ... Cancer discovery 6 (12), 1382-1399, 2016 | 713 | 2016 |
| Anti-TIM3 antibody promotes T cell IFN-γ–mediated antitumor immunity and suppresses established tumors SF Ngiow, B Von Scheidt, H Akiba, H Yagita, MWL Teng, MJ Smyth Cancer research 71 (10), 3540-3551, 2011 | 658 | 2011 |
| CD4+ CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer MJ Smyth, MWL Teng, J Swann, K Kyparissoudis, DI Godfrey, ... The Journal of Immunology 176 (3), 1582-1587, 2006 | 590 | 2006 |
| Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells Y Gao, F Souza-Fonseca-Guimaraes, T Bald, SS Ng, A Young, SF Ngiow, ... Nature immunology 18 (9), 1004-1015, 2017 | 564 | 2017 |
| TIGIT predominantly regulates the immune response via regulatory T cells S Kurtulus, K Sakuishi, SF Ngiow, N Joller, DJ Tan, MWL Teng, MJ Smyth, ... The Journal of clinical investigation 125 (11), 4053-4062, 2015 | 552 | 2015 |
| Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy J Stagg, S Loi, U Divisekera, SF Ngiow, H Duret, H Yagita, MW Teng, ... Proceedings of the National Academy of Sciences 108 (17), 7142-7147, 2011 | 551 | 2011 |
| Resistance to PD1/PDL1 checkpoint inhibition JS O'Donnell, GV Long, RA Scolyer, MWL Teng, MJ Smyth Cancer treatment reviews 52, 71-81, 2017 | 527 | 2017 |
| Immune-mediated dormancy: an equilibrium with cancer MWL Teng, JB Swann, CM Koebel, RD Schreiber, MJ Smyth Journal of Leucocyte Biology 84 (4), 988-993, 2008 | 526 | 2008 |
| CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis J Stagg, U Divisekera, H Duret, T Sparwasser, MWL Teng, PK Darcy, ... Cancer research 71 (8), 2892-2900, 2011 | 444 | 2011 |
| Cancer immunoediting by the innate immune system in the absence of adaptive immunity T O’Sullivan, R Saddawi-Konefka, W Vermi, CM Koebel, C Arthur, ... Journal of Experimental Medicine 209 (10), 1869-1882, 2012 | 407 | 2012 |
| From mice to humans: developments in cancer immunoediting MWL Teng, J Galon, WH Fridman, MJ Smyth The Journal of clinical investigation 125 (9), 3338-3346, 2015 | 399 | 2015 |
| Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses A Young, SF Ngiow, DS Barkauskas, E Sult, C Hay, SJ Blake, Q Huang, ... Cancer cell 30 (3), 391-403, 2016 | 364 | 2016 |
| PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux JS O’Donnell, D Massi, MWL Teng, M Mandala Seminars in cancer biology 48, 91-103, 2018 | 340 | 2018 |
